Table 1.
Subject disposition
| heiGHt | fliGHt | Total | ||
|---|---|---|---|---|
| Lonapegsomatropin, n (%) | Daily somatropin, n (%) | Lonapegsomatropin, n (%) | ||
| Enrolled and dosed in parent trial | 105 | 56 | 146 | 307 |
| Completed parent trial | 104 (99.0) | 55 (98.2) | 144 (98.6) | 303 (98.7) |
| Enrolled and dosed in enliGHtena | 103 (98.1) | 55 (98.2) | 140 (95.9) | 298 (97.0) |
| Active subjectsa | 100 (97.1) | 54 (98.2) | 129 (92.1) | 283 (95.0) |
| Withdrew from enliGHtenb | 3 (2.9) | 1 (1.8) | 4 (2.9) | 8 (2.7) |
| Completed enliGHtenb,c | 0 | 0 | 7 (5.0) | 7 (2.3) |
aDenominator based on subjects who were enrolled and dosed in parent trial.
bDenominator based on subjects enrolled and dosed in the enliGHten trial.
cA designation of enliGHten trial “completer” reflects that, based on investigator judgement, these subjects have reached satisfactory height and that it is no longer necessary for the subject to continue in the trial and receive treatment with pediatric doses of growth hormone therapy. Trial completion was required when there is evidence of closed epiphyses (bone age >14.0 years for females and >16.0 years for males).